Drug Information Bulletin

Drug Information Centre (DIC) Indian Pharmaceutical Association

Bengal Branch Tele fax: 033 24612776, E-mail: ipabengal.dic@gmail.com Web Site: http://www.ipabengal.org Contact: 09830136291

Volume: 06

Number: 30

4th November 2012

Content Final Report of FIP Challenge on TB Round 1 published in August 2012 by SEARPharm Forum Cipla cuts prices of 3 cancer drugs by up to 63% Supreme Court of Canada invalidates Pfizers Viagra Patent Five common causes of Medical Device failure The 15 best selling drugs of 2012 Forthcoming Events

Final Report of FIP Challenge on TB Round 1 published in August 2012 by SEARPharm Forum

For details: http://www.searpharm.org/resources/PDF_files/REPORT%20final.pdf

Page

Cipla cuts prices of 3 cancer drugs by up to 63% Cipla, one of Indias largest generic-drug manufacturers, on Thursday said it is reducing prices of three of its anti-cancer drugs by up to 63 per cent. According to the company, the move is part of its commitment to make medicines affordable and accessible, particularly in anti-cancer medication. The company has reduced the price of Erlotinib (Erlocip), Docetaxel (Docetax) and Capecitabine (Capegard). These drugs are for the treatment of lung and pancreatic cancer, breast cancer, head and neck cancer, gastric cancer, bladder, colorectal and colon cancers.

In May, Cipla had announced a similar price cut in three major anti-cancer drugs Sorafenib (Soranib), Gefitinib (Gefticip) and Temozolomide (Temoside). Continuing its contribution towards affordable and accessible treatment for patients, Cipla extends the work done in HIV/AIDS and Malaria to now includes Cancer, not only in India but globally, said Y K Hamied, chairman and managing director, Cipla. According to Cipla, the company has always been committed to the treatment and care of cancer patients. As part of this commitment, in 1997, it established the Cipla Palliative Care and Training Centre in Pune, to provide care to advanced stage cancer patients. The centre provides free treatment and has cared for over 8,000 patients till date. It has also trained a large number of nurses in advanced palliative care.
Ref. http://www.aalatimes.com/2012/11/09/cipla-reduces-prices-of-3-cancer-drugs-by-up-to-63/

Page

Supreme Court of Canada invalidates Pfizers Viagra Patent The Supreme Court of Canada has invalidated Pfizer's Viagra patent, opening the marketplace to cheaper versions of the popular erectile dysfunction drug. In a 7 to 0 decision, the high court sided with Teva Canada's challenge of the legitimacy of the patent. It annulled Pfizer's patent, saying it tried to "game" the system. The Teva victory means the company can begin selling its own version of the drug. The ruling wipes out Pfizer's market dominance with Viagra, whose patent was to have expired in 2014. Source: PharmaLive.com Five common causes of Medical Device failure Medical device failures can be disastrous, but they can be quickly resolved if a company takes immediate action to determine the cause of failure. This article outlines a list of five common causes of medical device failures and tips on how testing can pinpoint them. For details-http://www.qmed.com The 15 best selling drugs of 2012 Some of the biggest blockbusters known to the pharma industry have dropped off the patent cliff and tumbled into the brutal land of generic therapies, where low-priced competition lays sales to waste. The once-mighty Lipitor is finished as a big earner, as we see in our new list of the 15 top-selling pharmaceuticals 1. HUMIRA Drug: Adalimumab The companies: Abbott Laboratories/Eisai Estimated worldwide sales 2012: $9.48 billion 2. ENBREL The drug: Etanercept

The companies: Amgen/Pfizer/Takeda Pharmaceutical Estimated worldwide sales 2012: $8.37 billion 3. ADVAIR/SERETIDE The drugs: Fluticasone propionate The company: GlaxoSmithKline Estimated worldwide sales 2012: $8 billion 4. REMICADE The drug: Infliximab Company: Johnson & Johnson/Merck/Mitsubishi Tanabe Pharma Estimated worldwide sales 2012: $7.67 billion 5. RITUXAN The drug: Rituximab Company: Roche Estimated worldwide sales 2012: $6.94 billion 6. CRESTOR The drug: Rosuvastatin calcium Company: AstraZeneca/Shionogi Estimated worldwide sales 2012: $6.65 billion 7. LANTUS The drug: Insulin Glargine (rDNA origin) Company: Sanofi Estimated worldwide sales 2012: $6.12 billion 8. HERCEPTIN The drug: Trastuzumab The company: Roche Estimated worldwide sales 2012: $6.08 billion 9. AVASTIN The drug: Bevacizumab The company: Roche Estimated worldwide sales 2012: $5.98 billion

Page

Forthcoming Events: 10. LIPITOR The drug: Atorvastatin calcium The companies: Pfizer/Astellas Pharma/Jeil Pharmaceutical Estimated worldwide sales for 2012: $5.55 billion 11. ABILIFY The drug: Aripriprazole The companies: Bristol-Myers Squibb/Otsuka Holdings Estimated worldwide sales for 2012: $5.38 billion 12. PLAVIX The drug: Clopidogrel Bisuplhate The companies: Sanofi/Bristol-Myers Squibb Estimated worldwide sales for 2012: $5.11 billion 13. CYMBALTA The drug: Duloxetine HCl The companies: Eli Lilly/Shionogi Estimate worldwide sales for 2012: $5.01 billion 14. GlEEVEC The drug: Imatinib Mesylate The company: Novartis Estimated worldwide sales 2012: $4.72 billion 15. SPIRIVA The drug: Tiotropium Bromide The company: Boehringer Ingelheim Estimated worldwide sales 2012: $4.49 billion
Ref. http://www.fiercepharma.com/special-reports/15best-selling-drugs-2012

IPA Bengal Branch celebrating 51st National Pharmacy Week 25th November-2nd December 2012 Theme: Pharmacist in Public Health Tentative programme: 25.11.2012: Inauguration at Sisir Muncha, Kolkata 26.11.2012: Seminar at CIPT, Ulubeia 27.11.2012: Hospital Pharmacy Day 29.11.2012: Rally & Seminar at Institute of Pharmacy, Kalyani 30.11.2012: Industrial Pharmacy Day 01.12.2012: Celebration at Siliguri 02.12.2012: Seminar at DSP, Durgapur 02.12.2012: Cultural Programme at Aban Mahal (CLT), Kolkata

First International Conference of International Society for Pharmacoeconomics and Outcome Research-India Chapter Date: th 23-24 November 2012 Venue:
India Habitat Centre, Jacaranda Hall Lodhi Road, New Delhi - 110003, India

For Details Contact: Prof. S. K. Gupta President, ISPOR-India Chapter E-Mail: skgup@hotmail.com Web site: www.ispor.org

Page